Jason Baum

838 citations

30 papers · 656 indexed · h-index 11

Impact in

Aging top 10%
Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies

Papers in ⓘ

Oncology 19
- Cancer Immunotherapy and Biomarkers 9
- HER2/EGFR in Cancer Research 5
- Cancer Treatment and Pharmacology 3
Molecular Biology 11
- Glycosylation and Glycoproteins Research 4

Co-authors: Kimberly McCall (4 shared papers)Jeanne S. Peterson (2 shared papers)Hermann Steller (1 shared paper)Eli Arama (1 shared paper)Alexey A. Lugovskoy (9 shared papers)Birgit Schoeberl (5 shared papers)Ulrik B. Nielsen (6 shared papers)Sharlene Adams (7 shared papers)
Journals: Journal of Clinical Oncology (8 papers)Molecular Cancer Therapeutics (4 papers)Clinical Cancer Research (3 papers)Cancer Research (3 papers)Journal of Thoracic Oncology (2 papers)
Partner nations: United States China South Korea

In The Last Decade

Jason Baum

30 papers receiving 651 citations

Peers

Countries citing papers authored by Jason Baum

Since Specialization

Citations

This map shows the geographic impact of Jason Baum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Baum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Baum more than expected).

Fields of papers citing papers by Jason Baum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Baum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Baum. The network helps show where Jason Baum may publish in the future.

Co-authors

The 25 scholars most cited alongside Jason Baum, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jason Baum Line = papers co-authored together Jason Baum links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Programmed cell death in the germline Seminars in Cell and Developmental Biology ·Jason Baum, J.P. St. George, Kimberly McCall	2005	111
2	Germline Cell Death Is Inhibited by P-Element Insertions Disrupting the dcp-1/pita Nested Gene Pair in Drosophila Genetics ·Bonni Laundrie, Jeanne S. Peterson, Jason Baum, Jeffrey C. Chang, Dana Fileppo, Sharona R Thompson, Kimberly McCall	2003	97
3	MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors Molecular Cancer Therapeutics ·Jonathan B. Fitzgerald, Bryan W. Johnson, Jason Baum, Sharlene Adams, Sergio Iadevaia, Jian Tang, Victoria Rimkunas, Lihui Xu, Neeraj Kohli, Rachel Rennard, Maja Razlog, Yang Jiao, Brian D. Harms, Kenneth J. Olivier, Birgit Schoeberl, Ulrik B. Nielsen, Alexey A. Lugovskoy	2013	87
4	Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial Cancer Research ·Connie Wong, Jason Baum, Angela Silvestro, Michael T. Beste, Bharani Bharani-Dharan, Siyan Xu, Ying A. Wang, Tony Wang, Margaret F. Prescott, Lynne Krajkovich, Margaret Dugan, Paul M. Ridker, Anne‐Marie Martin, E. C. Svensson	2020	63
5	The Drosophila caspases Strica and Dronc function redundantly in programmed cell death during oogenesis Cell Death and Differentiation ·Jason Baum, Eli Arama, Hermann Steller, Kimberly McCall	2007	62
6	Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study Journal of Thoracic Oncology ·Enriqueta Felip, Filippo de Braud, Michela Maur, Herbert H. Loong, Alice T. Shaw, Johan Vansteenkiste, Thomas John, Geoffrey Liu, Martijn P. Lolkema, Giovanni Selvaggi, Vanessa Giannone, Pilar Cazorla, Jason Baum, O. Alejandro Balbin, Luojun Wang, Yvonne Lau, Jeffrey W. Scott, Daniel Shao-Weng Tan	2019	60
7	Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer Clinical Cancer Research ·Adam J. Camblin, Emily A. Pace, Sharlene Adams, Michael D. Curley, Victoria Rimkunas, Lin Nie, Gege Tan, Troy Bloom, Sergio Iadevaia, Jason Baum, Charlene Minx, Akos Czibere, Chrystal U. Louis, Daryl C. Drummond, Ulrik B. Nielsen, Birgit Schoeberl, J. Marc Pipas, Robert M. Straubinger, Vasileios Askoxylakis, Alexey A. Lugovskoy	2018	44
8	Rapid optimization and prototyping for therapeutic antibody-like molecules mAbs ·Lihui Xu, Neeraj Kohli, Rachel Rennard, Yang Jiao, Maja Razlog, Kathy Zhang, Jason Baum, Bryan W. Johnson, Jian Tang, Birgit Schoeberl, Jonathan B. Fitzgerald, Ulrik B. Nielsen, Alexey A. Lugovskoy	2013	21
9	DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish Journal of Clinical Oncology ·Samuel J. Klempner, Mohamad Bassam Sonbol, Zev A. Wainberg, Hope E. Uronis, Vi K. Chiu, Aaron J. Scott, S. Iqbal, Mohamedtaki Abdulaziz Tejani, Vincent Chung, Melissa C Stilian, Mathis Thoma, Ying Zhang, Michael H. Kagey, Jason Baum, Cynthia A. Sirard, Rachel A. Altura, Jaffer A. Ajani	2024	12
10	Validation of a DKK1 RNAscope chromogenic in situ hybridization assay for gastric and gastroesophageal junction adenocarcinoma tumors Scientific Reports ·Charles C. Caldwell, James B. Rottman, Will Paces, Elizabeth Bueche, Sofia Reitsma, Joseph Gibb, Vitria Adisetiyo, Michael Haas, Heidi Heath, Walter Newman, Jason Baum, Roberto Gianani, Michael H. Kagey	2021	11
11	A multicenter phase II study of istiratumab (MM-141) plus nab-paclitaxel (A) and gemcitabine (G) in metastatic pancreatic cancer (MPC). Journal of Clinical Oncology ·Andrew H. Ko, James H. Murray, Kerry Horgan, Julia Dauer, Michael Curley, Jason Baum, Chrystal U. Louis, Alexey A. Lugovskoy	2016	10
12	Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial. PubMed ·Edward H. Giannini, Karyl S. Barron, Charles H. Spencer, Donald A. Person, Jason Baum, B Bernstein, D W Kredich, J C Jacobs, Lawrence Zemel, Donna L. Gibbas	1991	10
13	A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA). Journal of Clinical Oncology ·Samuel J. Klempner, Bassam Bassam Sonbol, Zev A. Wainberg, Hope E. Uronis, Vi K. Chiu, Aaron J. Scott, Syma Iqbal, Mohamedtaki Abdulaziz Tejani, Melissa C Stilian, Mathis Thoma, Michael H. Kagey, Jason Baum, Cynthia A. Sirard, Rachel A. Altura, Jaffer A. Ajani	2023	10
14	DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial. Journal of Clinical Oncology ·Samuel J. Klempner, Joseph Chao, Hope E. Uronis, Cynthia A. Sirard, Michael H. Kagey, Jason Baum, James Song, Jin Wang, In-Ho Kim, Keun Wook Lee, Do‐Youn Oh, Bassam Bassam Sonbol, Zev A. Wainberg, Jaffer A. Ajani	2022	9
15	Visualizing Apoptosis Humana Press eBooks ·Kimberly McCall, Jason Baum, Kristen Cullen, Jeanne S. Peterson	2004	7
16	CANOPY-A: A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer (NSCLC). Journal of Clinical Oncology ·Edward B. Garon, Andrea Ardizzoni, Fabrice Barlési, Byoung Chul Cho, Pedro De Marchi, Yasushi Goto, Shun Lü, Luis Paz‐Ares, David R. Spigel, Michael Thomas, Bijoyesh Mookerjee, Pilar Cazorla Arratia, Jason Baum, Yi-Yang Yvonne Lau, Zewen Zhu, James Chih‐Hsin Yang	2019	7
17	A phase 1 study of MM-141, a novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3, in relapsed or refractory solid tumors European Journal of Cancer ·Steve Isakoff, R. Bahleda, MN Saleh, Rodolfo Bordoni, Anthony F. Shields, Julia Dauer, Michel Curley, Jason Baum, Ty McClure, Chrystal U. Louis, J.C. Soria	2016	5
18	CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC). Journal of Clinical Oncology ·Edward B. Garon, Andrea Ardizzoni, Fabrice Barlési, Byoung Chul Cho, Pedro De Marchi, Yasushi Goto, Dariusz M. Kowalski, Shun Lü, Luis Paz‐Ares, David R. Spigel, Alexander I. Spira, Michael Thomas, Mimi Leung, Jason Baum, Zewen Zhu, Maria do Socorro Oliveira Portella, James Chih‐Hsin Yang	2020	5
19	Effect of MM-141 on gemcitabine and nab-paclitaxel potentiation in preclinical models of pancreatic cancer through induction of IGF-1R and ErbB3 degradation. Journal of Clinical Oncology ·Emily Pace, Sharlene Adams, Adam J. Camblin, Michael Curley, Victoria Rimkunas, Lin Nie, Sergio Iadevaia, Gege Tan, Jason Baum, Akos Czibere, Alexey A. Lugovskoy	2015	4
20	Abstract C103: Targeting IL-1β pathway for cancer immunotherapy Molecular Cancer Therapeutics ·Pushpa Jayaraman, John M. Millholland, Neil A. O’Brien, Connie Wong, Rohan Diwanji, Muchun Wang, Elizabeth Choi, Ronald Linnartz, Kristine Rose, Vanessa Rodrik-Outmezguine, Marc R. Pelletier, Alexander Savchenko, Tong Luo, Valerie Rezek, Scott G. Kitchen, Jason Baum, Catherine Sabatos-Peyton, Anne‐Marie Martin, Glenn Dranoff	2019	3

About Jason Baum

Jason Baum is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology and Cancer Research, having authored 30 papers that have together received 656 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), HER2/EGFR in Cancer Research (5 papers), Gastric Cancer Management and Outcomes (5 papers), Glycosylation and Glycoproteins Research (4 papers), Cancer, Hypoxia, and Metabolism (4 papers), Lung Cancer Treatments and Mutations (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Cancer Treatment and Pharmacology (3 papers). The work is most often cited by research in Aging (31 citations), Oncology (258 citations), Immunology (141 citations), Molecular Biology (348 citations) and Radiology, Nuclear Medicine and Imaging (103 citations). Jason Baum has collaborated with scholars based in United States, China and South Korea. Frequent co-authors include Kimberly McCall, Jeanne S. Peterson, Hermann Steller, Eli Arama, Alexey A. Lugovskoy, Birgit Schoeberl, Ulrik B. Nielsen, Sharlene Adams, Victoria Rimkunas and Sergio Iadevaia. Their work appears in journals such as Journal of Clinical Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, Cancer Research and Journal of Thoracic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact